Molnupiravir Treatment for COVID-19 in People at Higher Risk in the Community: Outcomes from the PANORAMIC Randomised Controlled Trial at Three and Six …
V Harris, J Holmes, O Gbinigie, NM Rahman… - papers.ssrn.com
Objectives: Treating COVID-19 infection with antiviral drugs may reduce the longer-term
impact of the illness, but no randomised controlled trials have yet reported on the …
impact of the illness, but no randomised controlled trials have yet reported on the …
Molnupiravir detection by tandem mass spectrometry
DE Onmaz, FH Yerlikaya, M Onmaz - Archives of Current Medical … - dergipark.org.tr
Background: After the COVID-19 epidemic that broke out in 2019, studies on antiviral drugs
accelerated. In clinical studies with both re-purposed drugs and newly discovered drugs, the …
accelerated. In clinical studies with both re-purposed drugs and newly discovered drugs, the …
[PDF][PDF] Actualización sobre eficacia y seguridad de molnupiravir en pacientes con COVID-19 con alto riesgo de desarrollo de enfermedad grave
M Inthamoussu, F Garafoni… - … , 2023; 14 (2), 2023 - boletinfarmacologia.hc.edu.uy
Molnupuravir es un antiviral análogo nucleosídico que inhibe la replicación del SARS-CoV-
2, aumentando el número de alteraciones genéticas en el ARN. En junio del 2022, el Centro …
2, aumentando el número de alteraciones genéticas en el ARN. En junio del 2022, el Centro …